← Back to patent-cliff list
Tuvutromstat
Tier C — Watch / tradeTuvutromstat
Ideaya Biosciences Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Mat2A
Indications (approved)：Non-small cell lung cancer, Urothelial carcinoma, Solid tumour, Bladder cancer, Bile duct cancer, 间皮组织肿瘤, Oesophageal cancer, 食道腺癌
Regional status
US
Phase II
2023-08-01
EU
Phase II
2023-08-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Tuvutromstat?
Approved indications include: Non-small cell lung cancer, Urothelial carcinoma, Solid tumour, Bladder cancer, Bile duct cancer, 间皮组织肿瘤, Oesophageal cancer, 食道腺癌.
When does the Tuvutromstat patent expire?
No public expiry year is available for Tuvutromstat yet; this page updates once verified.
How do I get a quote for Tuvutromstat intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02